Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2025
Predictive biomarkers for valproic acid-induced hepatotoxicity in Chinese patients with epilepsy: the role of metabolites and genetic polymorphisms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wen Dingsheng, Chen Zhuojia, Chen Ziyi, Bai Xue, Li Hongliang, Chen Juan, Dai Qiling, Zhong Guoping, Qin Jiaming, Ni Guanzhong, Huang Min, Zhou Liemin, Wang Xueding
Аннотация
Valproic acid (VPA) is a widely used antiepileptic drug, but its hepatotoxicity limits usage. This study explored biomarkers and genetic factors associated with VPA-induced liver injury in 200 Chinese epileptic patients on VPA monotherapy. We analyzed VPA and its metabolites (4-ene-VPA, 3-OH-VPA, 4-OH-VPA, 2-PGA), liver function, and 22 gene polymorphisms. Patients with abnormal liver function (ANLFT) had significantly higher 4-ene-VPA levels than those with normal liver function (NLFT). The GG genotype of CPT1A rs2228502 was associated with elevated 4-ene-VPA levels. SNPs in ACOT1, PPARα, FFAR2, NQO1, and NRF2 showed significant differences between groups. Logistic regression identified NRF2 rs59288687 and NQO1 rs10517 as protective factors against hepatotoxicity. In conclusion, elevated 4-ene-VPA and genetic variants, including CPT1A rs2228502, NRF2 rs59288687, and NQO1 rs10517, influence hepatotoxicity risk, providing insights for individualized treatment strategies.